

# 3rd Alpine Winter Conference on Medicinal and Synthetic Chemistry

## Confirmed Speakers

### Keynote Speakers

#### KL01 - Attenuating Oncogenic Transcription with Small Molecules

(SANOFI-AVENTIS DEUTSCHLAND GMBH)



Prof. Angela KOEHLER  
(MIT KOCH INSTITUTE FOR INTEGRATIVE CANCER RESEARCH, Cambridge, United States)

#### KL03 - Functionalization of N-Heterocycles using Li, Mg, and Zn Organometallics



Prof. Paul KNOCHER  
(LUDWIG MAXIMILIANS UNIVERSITY, Munich, Germany)

#### KL02 - Drug Discovery: Where are we Headed?



Dr Wendy YOUNG  
(MPM CAPITAL, Brisbane, CA, United States)

### The "Catalytic Cycle" of Complex Molecule Synthesis and Methodology Development

#### IL23 - Flow-based Methods for Chemical Peptide and Protein Synthesis".



Prof. Nina HARTRAMPF  
(UNIVERSITY OF ZURICH, Zürich, Switzerland)

#### IL24 - Prins Cyclization in Natural Product Synthesis



Prof. Ang LI  
(SHANGHAI INSTITUTE OF ORGANIC CHEMISTRY, Shanghai, China)

#### IL25 - Taming Multifaceted Nickel Catalysts: An Academic Fascination



Prof. Ruben MARTIN  
(INSTITUTE OF CHEMICAL RESEARCH OF CATALONIA, Tarragona, Spain)

#### IL26 - Computationally Augmented Total Synthesis



Dr Timothy NEWHOUSE  
(YALE UNIVERSITY, New Haven, United States)

### Automation and Machine Learning Applications for Medicinal Chemistry

#### IL09 - Enabling Fragment-based Drug Discovery (FBDD) with Automated Synthesis Technologies

# 3rd Alpine Winter Conference on Medicinal and Synthetic Chemistry

## Confirmed Speakers



Dr Rachel GRAINGER  
(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom)

### IL10 - Rapid Development of Robust Reactions and Multi-Step Syntheses



Prof. Alexei LAPKIN  
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)

### IL11 - High-Throughput Experimentation Capabilities to Accelerate Discovery Chemistry



Dr Iulia STRAMBEANU  
(JOHNSON AND JOHNSON, King of Prussia, United States)

## Methodologies to Understand Cellular Target Interaction

### IL01 - Intracellular Oligonucleotide Distribution and Protein Binding



Dr Alice GHIDINI  
(ASTRAZENECA, Gothenburg, Sweden)

### IL04 - Lessons in Transcellular Membrane Permeability Re-Learned



Dr Mike HANN  
(GSK MEDICINES RESEARCH CENTRE, Stevenage, United Kingdom)

### IL03 - Molecular Chameleonism and Cell Permeability of Drugs and PROTACs in the bRo5 Space



Prof. Jan KIHLEBERG  
(UPPSALA UNIVERSITY, Uppsala, Sweden)

### IL02 - Monitoring Drug Selectivity and Target Engagement Across Systems – Thermal Shift Assay in Drug Discovery



Dr Anna RUTKOWSKA-KLUTE  
(GSK, Heidelberg, Germany)

## Understanding PK and PK/PD relationships in drug discovery - Target Mediated Drug Disposition

### IL17 - Concept of Pharmacologic Target-Mediated Drug Disposition (TMDD) in Large-Molecule and Small-Molecule Compounds



Prof. Guohua AN  
(THE UNIVERSITY OF IOWA COLLEGE OF PHARMACY, Iowa City, United States)

# 3rd Alpine Winter Conference on Medicinal and Synthetic Chemistry

## Confirmed Speakers

### IL18 - Understanding the PKPD and ADME of PF-07059013: An Allosteric Modulator of a High Abundance Target



Dr Kevin BEAUMONT  
(ASTRAZENECA, Cambridge, United Kingdom)

### IL16 - General Introduction to TMDD



Dr David FAIRMAN  
(GSK, Cambridge, United Kingdom)

### IL19 - Importance of Mechanistic Models in AHD Prediction (IL)



Dr Birgit SCHOEBERL  
(NOVARTIS INSTITUTE FOR BIOMEDICAL RESEARCH, Cambridge, MA, United States)

## Drug Discovery Tales (II)

### OC06 - Towards the Design of Cell Division Cycle 25 Phosphatases Inhibitors as Anticancer Agents



Dr Carmen CERCHIA  
(UNIVERSITY OF NAPLES FEDERICO II, Naples, Italy)

### OC04 - Dissociative Inhibitors of Thymidylate Synthase Homodimer Accelerate its Proteasomal Degradation and Inhibit Cancer Growth in Vivo



Prof. Maria Paola COSTI  
(UNIVERSITY OF MODENA AND REGGIO EMILIA, Modena, Italy)

### OC05 - Rational Design of Light-Controlled Bioactive Compounds for Photopharmacology



Mr Piermichele KOBURI  
(UNIVERSITY OF GRONINGEN FSSC, Groningen, The Netherlands)

### OC03 - Discovery of a Selective ALK2 Kinase Inhibitor for the Treatment of a Rare Genetic Bone Disease



Dr Thomas ULLRICH  
(NOVARTIS PHARMA AG, Basel, Switzerland)

## Increasing sp<sup>3</sup> Fragment Options: Advances in the Synthesis of Small Ring Systems

### IL12 - Exploring and exploiting propellanes



Prof. Ed ANDERSON  
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

# 3rd Alpine Winter Conference on Medicinal and Synthetic Chemistry

## Confirmed Speakers

### IL15 - No Strain, No Gain: Advances in the Synthesis and Design of New Classes of Building Blocks



Prof. Kevin BROWN  
(INDIANA UNIVERSITY, Bloomington, United States)

### IL13 - The Next Generation of BCPs: Exploring Substitutions on the Bridge



Dr Xiaoshen MA  
(MERCK & CO., INC, Boston, United States)

### IL14 - Synthesis and Functionalization of Cyclopropane Derivatives



Dr Sophie ROUSSEAU  
(UNIVERSITY OF TORONTO, Toronto, Canada)

## Covalent Targeting: Innovating for the Future

### IL22 - Studies with Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors



Dr Agustin CASIMIRO-GARCIA  
(PFIZER, United States)

### IL20 - Lysine-Targeting Covalent Inhibitors



Dr Matthew CHEESEMAN  
(THE INSTITUTE OF CANCER RESEARCH, Sutton, United Kingdom)

### IL21 - Reversible-covalent Inhibitors of the Kinase Activity of FGFR4



Dr Robin FAIRHURST  
(NOVARTIS, Basel, Switzerland)

## Drug Discovery Tales (I)

### OC01 - Design and Synthesis of Novel RNA Binders for Therapeutic Applications



Ms Maurinne BONNET  
(ICN, NICE, France)

### OC02 - Is Resistance Futile? Discovery of Clinical Candidate AZD3229, A Pan-Mutant C-KIT Inhibitor



Dr James SMITH  
(ASTRAZENECA, Cambridge, United Kingdom)

## Targeting Unstructured Proteins

# 3rd Alpine Winter Conference on Medicinal and Synthetic Chemistry

## Confirmed Speakers

### IL05 - Innovative Strategies to Target Non-Coding RNAs with Synthetic Ligands



Dr Maria DUCA  
(UNIVERSITY OF CÔTE D'AZUR, Nice, France)

### IL07 - Drugging RNA – A Structure-based Approach



Dr Jacques DUMAS  
(ARRAKIS THERAPEUTICS, Boston, United States)

### IL06 - Targeting Transcription Factors for Treating Human Cancers and Auto Immune and Inflammatory Diseases



Dr Dorian FABBRO  
(CELLESTIA BIOTECH AG, Basel , Switzerland)

### IL08 - Design of Zotatifin (eFT226), a First-in-Class Inhibitor of the RNA Helicase eIF4A



Dr Christian NILEWSKI  
(GENENTECH, South San Francisco, United States)